StockDuty
Jun 24, 2026 06:21 PM ET
Catalyst
FDA/Bio
$GALT
- GALECTIN DE-RISKS BELAPECTIN PATH WITH FDA ALIGNMENT — SETS STAGE FOR PHASE 3 UPSIDE
What changed
$GALT - GALECTIN DE-RISKS BELAPECTIN PATH WITH FDA ALIGNMENT — SETS STAGE FOR PHASE 3 UPSIDE
Why it matters
FDA alignment de-risks belapectin, setting stage for phase 3 upside.
Sources
seekingalpha
Related signals
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →
IONIS PHARMACEUTICALS, INC. (IONS) DISCUSSES FDA APPROVAL OF TRYNGOLZA FOR SEVERE HYPERTRIGLYCERIDEMIA AND ACUTE PANCREA →
HOYA ( TSE : 7741 ) STOCK AFTER NEW FDA CLEARANCE WEIGHING RICH VALUATION AGAINST GROWTH POTENTIAL →